Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Taysha Gene Therapies (TSHA) Net Income towards Common Stockholders (2022 - 2025)

Historic Net Income towards Common Stockholders for Taysha Gene Therapies (TSHA) over the last 4 years, with Q3 2025 value amounting to -$32.7 million.

  • Taysha Gene Therapies' Net Income towards Common Stockholders fell 2824.4% to -$32.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$99.9 million, marking a year-over-year decrease of 33882.4%. This contributed to the annual value of -$89.3 million for FY2024, which is 1995.95% up from last year.
  • Latest data reveals that Taysha Gene Therapies reported Net Income towards Common Stockholders of -$32.7 million as of Q3 2025, which was down 2824.4% from -$26.9 million recorded in Q2 2025.
  • In the past 5 years, Taysha Gene Therapies' Net Income towards Common Stockholders ranged from a high of $47.7 million in Q4 2023 and a low of -$117.1 million during Q3 2023
  • Its 4-year average for Net Income towards Common Stockholders is -$29.9 million, with a median of -$25.5 million in 2024.
  • Over the last 5 years, Taysha Gene Therapies' Net Income towards Common Stockholders had its largest YoY gain of 18667.89% in 2023, and its largest YoY loss of 34138.8% in 2023.
  • Quarter analysis of 4 years shows Taysha Gene Therapies' Net Income towards Common Stockholders stood at -$55.1 million in 2022, then soared by 186.68% to $47.7 million in 2023, then plummeted by 139.35% to -$18.8 million in 2024, then crashed by 74.25% to -$32.7 million in 2025.
  • Its Net Income towards Common Stockholders was -$32.7 million in Q3 2025, compared to -$26.9 million in Q2 2025 and -$21.5 million in Q1 2025.